Comments on: Tarenflurbil appears to have no effect on cognition, activities of daily living in early Alzheimer’s. Medscape (12/15, Harrison) reported that, according to a study published Dec. 16 in the Journal of the American Medical Association, “tarenflurbil (Flurizan, Myriad Genetics), a gamma-secretase modulator, has no effect on cognition or activities of daily living (ADL)…in patients with mild” Alzheimer’s disease. In a “large phase 3, randomized, placebo-controlled trial” of 1,684 patients with mild Alzheimer’s disease, Boston University School of Medicine researchers found “virtually no difference between patients receiving active therapy vs. placebo controls at 18 months in either coprimary endpoints of cognition or ADL.” They also found “no differences between the two treatment groups on secondary outcome measures.”

Comments on: Tarenflurbil appears to have no effect on cognition, activities of daily living in early Alzheimer’s. Medscape (12/15, Harrison) reported that, according to a study published Dec. 16 in the Journal of the American Medical Association, “tarenflurbil (Flurizan, Myriad Genetics), a gamma-secretase modulator, has no effect on cognition or activities of daily living (ADL)…in patients with mild” Alzheimer’s disease. In a “large phase 3, randomized, placebo-controlled trial” of 1,684 patients with mild Alzheimer’s disease, Boston University School of Medicine researchers found “virtually no difference between patients receiving active therapy vs. placebo controls at 18 months in either coprimary endpoints of cognition or ADL.” They also found “no differences between the two treatment groups on secondary outcome measures.” http://buydimebon.com/news/tarenflurbil-appears-to-have-no-effect-on-cognition-activities-of-daily-living-in-early-alzheimers-medscape-1215-harrison-reported-that-according-to-a-study-published-dec-16-in-the-journal/390/ Russian Antihistamine Drug to Treat Alzheimer’s Disease Sun, 20 May 2012 06:45:42 +0000 http://wordpress.org/?v=2.5.1